secwatch.observer — SEC 8-K summary
======================================

Issuer:     Insight Molecular Diagnostics Inc. (IMDX)
CIK:        0001642380
Form:       8-K
Filed at:   2022-08-10T23:59:59+00:00
Accession:  0001493152-22-021889
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 2.05, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oncocyte Q2 net loss $8.3M; plans RIF to cut $4.5M annual costs
---------------------------------------------------------------

- Net loss $8.3M ($0.07 EPS) vs $10.5M ($0.12 EPS) YoY; revenue $2.1M, flat.
- Reduction in force to cut annual cash comp costs by >$4.5M; severance ~$2.0M in Q3 2022.
- Closed underwritten offering of $32.8M and preferred stock offering of $4.9M in net proceeds.
- Cash $47.1M as of June 30; annualized op expense reduction of ~$12M expected in 2023.
- Appointed Gisela Paulsen President & COO and Anish John CFO, effective Aug 8, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1642380/000149315222021889/0001493152-22-021889-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1642380/000149315222021889/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-021889

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer